 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | cannabidiol (EMD-RX5) / Emyria
Trial initiation date: A Phase III study to investigate the effect of EMD-RX5 on symptoms of psychological distress in adults with chronic pain (EUDRACT) - Sep 1, 2023
P3, N=300, Recruiting, Sponsor: Emyria Ltd
Initiation date: Jan 2000 --> Jan 2023
- || cannabidiol (EMD-RX5) / Emyria
$ASX:EMD Emyria agrees licensing and commercialisation deal for EMD-RX5 https://t.co/MlrD4dbMH0 (Twitter) - Apr 4, 2023
- | cannabidiol (EMD-RX5) / Emyria
New P1 trial: A Phase I Clinical Trial comparing Pharmacokinetics of EMD-RX5 Cannabidiol (CBD) capsules to Epidyolex CBD oil in Healthy Volunteers. (EUDRACT) - Mar 19, 2022
P1, N=12, Recruiting, Sponsor: Emyria Ltd